Ms. Linda Kisa reports

CRESCITA COMPLETES ACQUISITION OF STRATEGIC ASSETS OF OCCY LABORATORY

Crescita Therapeutics Inc. has concluded the asset purchase agreement to acquire all of the non-real estate business assets of Occy Laboratory Inc., a Laval-based manufacturer and distributor of high-quality dermocosmetic products (the "Transaction"). The acquired assets include Occy's manufacturing equipment, inventory, customer network and intellectual property (the "Assets").

Pursuant to the terms of the Purchase Agreement, Crescita acquired the Assets for total cash consideration of $0.9 million. Occy's revenue for fiscal 2023, its most recently completed year-end, was approximately $1.5 million.

"We are very pleased with the financial terms of this acquisition and expect that it will be accretive to EBITDA once the integration is complete," stated Mr. Verreault. "This acquisition creates an exciting opportunity for us to accelerate growth and enhance our profitability."

The Transaction, conducted pursuant to the voluntary proceedings undertaken by Occy under the Bankruptcy and Insolvency Act, was approved by the Quebec Superior Court at a sale approval hearing on June 19, 2024, as previously announced.

Crescita will continue the commercial activities carried on by Occy prior to closing, while it integrates the Assets into its operations in the coming months.

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

We seek Safe Harbor.